



BUDAPEST 2019

# BUDAPEST

CONFERENCE OVERVIEW  
07–10 SEPTEMBER 2019

Clinical & Scientific  
Update 2019

Scientific Programme

[eta2019.com](http://eta2019.com)



**The CONGRESS REGISTRATION DESK will operate the following hours:**

<b>FRIDAY,</b>	<b>6th Sept.</b>	<b>16:00 – 18:00</b>
<b>SATURDAY,</b>	<b>7th Sept.</b>	<b>07:00 – 19:30</b>
<b>SUNDAY,</b>	<b>8th Sept.</b>	<b>07:30 – 19:00</b>
<b>MONDAY,</b>	<b>9th Sept.</b>	<b>07:30 – 19:15</b>
<b>TUESDAY,</b>	<b>10th Sept.</b>	<b>07:30 – 15:00</b>

**COMMERCIAL EXHIBITION Opening times**

<b>SATURDAY,</b>	<b>7th Sept.</b>	<b>09:00 – 18:00</b>
<b>SUNDAY,</b>	<b>8th Sept.</b>	<b>09:00 – 18:00</b>
<b>MONDAY,</b>	<b>9th Sept.</b>	<b>09:00 – 18:00</b>
<b>TUESDAY,</b>	<b>10th Sept.</b>	<b>09:00 – 15:00</b>

**MEDIA CHECK** **Opening times**  
**BIZET Room**

<b>SATURDAY,</b>	<b>7th Sept.</b>	<b>07:00 – 18:15</b>
<b>SUNDAY,</b>	<b>8th Sept.</b>	<b>07:30 – 18:00</b>
<b>MONDAY,</b>	<b>9th Sept.</b>	<b>07:30 – 18:00</b>
<b>TUESDAY,</b>	<b>10th Sept.</b>	<b>07:30 – 13:00</b>

The **42nd ANNUAL MEETING** of the **European Thyroid Association** has been accredited by the **European Accreditation Council for Continuing Medical Education (EACCME®)** for a maximum of **24 European CME credits (ECMEC®s)**.

## ETA Clinical Update

### Benign nodular goiter

VENUE  
Patria

08:00 - 12:00

Chairs: Tomasz Bednarczuk (Poland) & Thomas Brix (Denmark)

---

08:00 - 08:30 **Epidemiology and clinical picture of nodular goiter.  
Influence of iodine intake**  
*Allan Carle (Denmark)*

---

08:30 - 09:00 **Current role and value of fine-needle aspiration in nodular goiter.  
Ruling in or ruling out malignancy**  
*Ralf Paschke (Canada)*

---

09:00 - 09:30 **Role of isotope scan in nodular goiter.  
Is a warm/hot nodule always benign?**  
*Markus Luster (Germany)*

---

#### COFFEE BREAK

---

10:00 - 10:30 **Diagnostic role of ultrasound and  
elastosonography in nodular goiter**  
*Teresa Rago (Italy)*

---

10:30 - 11:00 **The role of radioiodine therapy, including the use  
of recombinant TSH, in benign nodular goiter**  
*Steen Bonnema (Denmark)*

---

11:00 - 11:30 **The role of surgery in benign nodular goiter:  
Impact on quality of life**  
*Marcin Barczynski (Poland)*

---

11:30 - 12:00 **In case of no surgery, how choose between simple  
follow-up and alternative treatments: ethanol injections  
and thermo-ablations?**  
*Hervé Monpeyssen (France)*

---

# ETA Basic Update: Thyroid development, regulation, function and pathology

VENUE  
Brahms

09:00 - 13:00

---

09:30 - 10:00    **Thyroid gland development**  
*Mikael Nilsson (Sweden)*

---

10:00 - 10:30    **In vitro thyroid gland (stem cells)**  
*Robert Opitz (Germany)*

---

10:30 - 11:00    **Thyroid hormone synthesis**  
*Peter Kopp (United States)*

---

## COFFEE BREAK

---

11:30 - 12:00    **Physiological regulation of the thyroid gland (TSH)**  
*Jukka Kero (Finland)*

---

12:00 - 12:30    **Thyroid Pathology: congenital hypo and hyperthyroidism**  
*Nadia Schoenmakers (United Kingdom)*

---

12:30 - 13:00    **Thyroid Pathology: benign and malignant neoplasia**  
*Lars Christian Moeller (Germany)*

---

ETA

European  
THYROID  
Association



**ETA Cancer Group: Thyroid Nodule****08:00 - 13:00**VENUE  
Liszt I-III

08:00 - 08:20

**WELCOME**

Laura Fugazzola (Italy) and Clara Alvarez (Spain)

**SESSION I****DIAGNOSIS OF THYROID NODULES**

Chairs: Malgorzata Oczko-Wojciechowska (Poland), Juan Carlos Galofré (Spain)

08:20 - 08:40

**Cytological classification***Ewa Stobiecka (Poland)*

08:40 - 09:00

**Prospective validation of ATA and ETA sonographic pattern risk of thyroid nodules selected for FNAC***Maria Grazia Castagna (Italy)*

09:00 - 09:20

**Risk of malignancy in thyroid cytology: the impact of the reclassification of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)***Miguel Melo (Portugal)*

09:20 - 09:40

**Is there a role for molecular analysis?***Carla Colombo (Italy)*

09:40 - 10:00

**Imaging biomarkers in cytological indeterminate nodules***Lisanne J. de Koster (Netherlands)***COFFEE BREAK****SESSION II****LECTURE: FRONTIER IN CLINICAL ADVANCES**

Chair: Barbara Jarzab (Poland)

10:30 - 11:00

**Targeted therapies in advanced medullary thyroid cancer***Manisha H. Shah (United States)***SESSION III****MANAGEMENT OF THYROID NODULES**

Chairs: Thera Links (Netherlands), Agnieszka Czarniecka (Poland)

11:05 - 11:25

**Minimally invasive treatments***Clara García (Spain)*

11:25 - 11:45

**Management of nodules in children***Hanneke Van Santen (Netherlands)*

11:45 - 12:05

**General Discussion of Sessions I-II-III**

Chairs: Christine Spitzweg (Germany) and Markus Luster (Germany)

12:05 - 12:30

**Difficult cases: Evaluation and Comments according to the ETA Cancer Group-Endo ERN Survey***Daria Handkiewicz-Junak (Poland)***(Cases to be prepared by the ETA CG committee):****FOCUS 1: Adult Thyroid Cancer FOCUS 2: Pediatric Thyroid cancer**

12:30 - 12:45

**General Assembly ETA Cancer Group**

12:45 - 13:00

**Closing remarks**

08:00 - 13:00

## Iodine Global Network - ETA

### SESSION I

Chairs: Gregory Gerasimov (Russian Federation), Rodrigo Moreno-Reyes (Belgium)

08:00 - 08:25 **Registration and Coffee/Tea**

08:25 - 08:30 **Introduction**  
*John Lazarus (United Kingdom)*

08:30 - 08:50 **Dietary iodine intake in Europe**  
*Sarah Bath (United Kingdom)*

08:50 - 09:10 **Thyroglobulin as a biomarker of iodine deficiency and excess in pregnancy**  
*Sandra Hunziker (Switzerland)*

09:10 - 09:30 **Long term effects of iodine fortification in Denmark – Good or Bad?**  
*Stig Andersen (Denmark)*

09:30 - 09:50 **Iodine status in Romanian schoolchildren, pregnant women and newborns**  
*Monica Livia Gheorghiu (Romania)*

### COFFEE/TEA and POSTERS

### SESSION II

Chairs: John Lazarus (United Kingdom) Paolo Vitti (Italy)

10:30 - 10:50 **Iodised salt and pregnancy - is it enough?**  
*Peter Taylor (United Kingdom)*

10:50 - 11:10 **No idea about iodine? Public perceptions**  
*Janis Hickey (United Kingdom)*

11:10 - 11:30 **The elimination of iodine deficiency in Greece and China; two different approaches**  
*Eftychia Koukkou (Greece)*

11:30 - 11:50 **Barriers to adequate iodine consumption in the UK**  
*Elle Perschke (United Kingdom)*

11:50 - 12:15 **Sustainable prevention of iodine deficiency disorders in Europe**  
*Attilio Caligiani (Belgium)*

12:15 - 13:00 **Lunch and close**

## ULTRASOUND COURSE

VENUE  
Bartok I-II

08:00 - 13:00

08:00 - 08:05 **Welcome and course objectives**

*Laszlo Hegedüs (Denmark)*

08:05 - 08:30 **Basics of ultrasound differential diagnostics of thyroid nodules**

*Steen Bonnema (Denmark)*

08:30 - 08:55 **TIRAD-systems**

*Laurence Leenhardt (France)*

08:55 - 09:00 **Case study 1**

09:00 - 09:25 **Cytopathology**

*Fernando Schmitt (Portugal)*

09:25 - 09:50 **The relation between discrete lesions on ultrasound and pathological nodules**

*Tamas Solymosi (Hungary)*

09:50 - 09:55 **Case study 2**

**COFFEE**

10:15 - 10:40 **The practical significance of neck compartments**

*Andrea Frasoldati (Italy)*

10:40 - 11:10 **US-guided interventions:  
sclerotherapy, radiofrequency and laser ablation**

*Laszlo Hegedüs (Denmark) and Enrico Papini (Italy)*

11:10 - 11:15 **Case study 3**

11:15 - 12:45 **Hands on Session - live patients and phantom**

12:45 - 13:00 **Course evaluation**

*Laszlo Hegedüs (Denmark) and Tamas Solymosi (Hungary)*



BUDAPEST 2019

**13:40 - 14:00 OPENING CEREMONY**

Laszlo Hegedüs (Denmark) and Endre V. Nagy (Hungary)

VENUE  
Patria**14:00 - 16:00****ORAL Session 1 Topic Highlights**

Chairs: Laszlo Hegedüs (Denmark) and Endre V. Nagy (Hungary)

VENUE  
Patria

14:00 - 14:20 **OP-01-01**  
**Treatment of advanced trk fusion thyroid cancer with larotrectinib**  
*Steven Waguespack (United States)*

14:20 - 14:40 **OP-01-02**  
**Zebrafish sbp2<sup>-/-</sup> mutant displays abnormal thyroid hormone metabolism, oxidative stress and aortopathy, recapitulating key features of human SBP2 deficiency**  
*Federica Marelli (Italy)*

14:40 - 15:00 **OP-01-03**  
**Genetic determinants of thyroid function in pregnant women, newborns and children.**  
*Tessa Mulder (Netherlands)*

15:00 - 15:20 **OP-01-04**  
**Prognostic significance of TERT promoter and BRAF mutations in cytologically suspicious or malignant thyroid nodules: a monocentric case series at a tertiary-level endocrinology unit**  
*Simona Censi (Italy)*

15:20 - 15:40 **OP-01-05**  
**Differences in directional transport of thyroid hormone in the human term placenta**  
*Zhongli Chen (Netherlands)*

15:40 - 16:00 **OP-01-06**  
**Birth defects after early pregnancy exposure to antithyroid drugs and abnormal maternal thyroid function among 1,243,353 children born in Denmark during a 20-year period**  
*Stine Linding Andersen (Denmark)*



16:00 – 17:00

## POSTER Session 1

VENUE

<b>P1-01-01 - 11</b>	<b>PS1: Autoimmunity 1</b> <i>Chair: Mario Salvi (Italy)</i>	<b>Bartok I</b>
<b>P1-02-12 - 22</b>	<b>PS1: Cancer Basic</b> <i>Chair: Garcilaso Riesco-Eizaguirre (Spain)</i>	<b>Liszt I</b>
<b>P1-03-23 - 32</b>	<b>PS1: Cancer Clinical 1</b> <i>Chair: Kalliopi Pazaitou-Panayiotou (Greece)</i>	<b>Liszt II</b>
<b>P1-04-33 - 44</b>	<b>PS1: Hypothyroidism</b> <i>Chair: Allan Carle (Denmark)</i>	<b>Liszt III</b>
<b>P1-05-45 - 54</b>	<b>PS1: Nodules 1</b> <i>Chair: Giorgio Grani (Italy)</i>	<b>Mozart I</b>
<b>P1-06-55 - 64</b>	<b>PS1: Orbitopathy</b> <i>Chair: Milos Zarkovic (Serbia)</i>	<b>Mozart II</b>
<b>P1-07-65 - 75</b>	<b>PS1: Pregnancy, Nutrition, Metabolism</b> <i>Chair: Alicja Hubalewska-Dydejczyk (Poland)</i>	<b>Mozart III</b>
<b>P1-08-76 - 85</b>	<b>PS1: Thyroid Hormone Action and HPT axis</b> <i>Chair: W. Edward Visser (Netherlands)</i>	<b>Strauss</b>

17:00 - 18:00

## ETA Industry-sponsored Satellite **SYMPOSIUM 1**

VENUE  
Patria

### 70 years of levothyroxine: A roadmap to the future

Chair: Leonidas Duntas (Athens, Greece)

#### The pharmacogenomics of thyroxine in treating the various faces of hypothyroidism

Emese Mezosi (Pecs, Hungary)

#### T4 plus T3 therapy: A fad or the future

David Cooper (Baltimore, US)

#### Treatment of hypothyroidism in the elderly: Is longevity any concern?

Bernadette Biondi, Naples (Italy)

**MERCK** organized and funded educational symposium

18:15 - 18:35

### Historical Vignette:

### Commemorating 70 years of antithyroid drugs

VENUE  
Patria

Chairs: Leonidas Duntas (Greece) and David Cooper (US)

18:35 - 19:20

### ETJ Lecture

VENUE  
Patria

Chairs: Wilmar Wiersinga (Netherlands) and Simon Pearce (United Kingdom)

19:30 - 22:00

### WELCOME Reception

VENUE  
Aula

08:00 - 09:30

**SYMPOSIUM 1** **US guided interventional therapy of nodular thyroid disease**VENUE  
Patria

Chairs: Laszlo Hegedüs (Denmark) and Károly Rucz (Hungary)

08:00 - 08:25 **ETA Questionnaire survey on current practice***Enrico Papini (Italy)*08:30 - 08:55 **ETA Guidelines on US interventional therapy of nodular disease***Hervé Monpeyssen (France)*09:00 - 09:25 **Therapy of microcarcinoma – active surveillance vs. Treatment (debate)***Eleonora Molinaro (Italy) and Juan Carlos Galofré (Spain)*

08:00 - 09:30

**SYMPOSIUM 2** **Thyroid Hormone regulation in inflammation and repair**VENUE  
Bartok II

Chairs: Monica Dentice (Italy) and Peter Lakatos (Hungary)

08:00 - 08:25 **Role of thyroid hormone in Inflammation***Anne van der Spek (Netherlands)*08:30 - 08:55 **Effects of thyroid hormone metabolism in bone and in fracture repair***Andrea Pollard (United Kingdom)*09:00 - 09:25 **The intracellular modulation of thyroid hormone regulates muscle injury and sarcopenia***Domenico Salvatore (Italy)*

10:00 - 11:30

**ORAL Session 2** **Thyroid Nodules and Ultrasound**VENUE  
Patria

Chairs: Peter Kopp (United States) and Gábor László Kovács (Hungary)

10:00 - 10:15 **OP-02-07****A multicenter validation study for the EU-TIRADS using histological diagnosis as gold standard***Pierpaolo Trimboli (Switzerland)*10:15 - 10:30 **OP-02-08****Inter-observer variation of ultrasound nodule characteristics and the diagnostic performance of five TIRADS classification systems***Tamas Solymosi (Hungary)*10:30 - 10:45 **OP-02-09****Long-term outcome following laser therapy of complex thyroid nodules***Helle Døssing (Denmark)*

10:45 - 11:00

**OP-02-10****Long-term efficacy of percutaneous laser ablation treatment of large benign thyroid nodules***Alessandro Brancatella (Italy)*

11:00 - 11:15

**OP-02-11****TIRADS system scores versus expert evaluations for nodule selection for fine needle aspiration: experts are better. A study employing ultrasound videos of 123 nodules evaluated by 7 experts from 7 different thyroid centers***Karoly Rucz (Hungary)*

11:15 - 11:30

**OP-02-12****Non-invasive follicular thyroid neoplasm with papillary-like nuclear features: an analysis of prospective data collected by the Italian Thyroid Cancer Observatory.***Valeria Ramundo (Italy)*

10:00 - 11:30

**ORAL Session 3 Thyroid Hormone, Metabolism and Action**VENUE  
**Bartok II**

Chairs: John Howard Duncan Bassett (United Kingdom) and Fekete Csaba (Hungary)

10:00 - 10:15

**OP-03-13****Age-dependent recovery from hyperglycaemia in hypothyroid Dio2-deficient zebrafish.***Veerle Darras (Belgium)*

10:15 - 10:30

**OP-03-14****Deiodinases are dynamically expressed in FAPs during muscle regeneration***Cristina Luongo (Italy)*

10:30 - 10:45

**OP-03-15****Release of endogenous 3-iodothyroacetic acid in a mouse model of short-term brain ischemia***Francesca Tozzi (Italy)*

10:45 - 11:00

**OP-03-16****T3-mediated cardiac hypertrophy is a physiological effect of canonical thyroid hormone receptor alpha action***Daniela Geist (Germany)*

11:00 - 11:15

**OP-03-17****The rs17606253 MCT10 polymorphism does not affect thyroid hormone levels in athyreotic patients***Fabio Maino (Italy)*

11:15 - 11:30

**OP-03-18****Transthyretin regulates neural stem cell fate in the adult mouse brain.***Pieter Vancamp (France)*

11:30 - 12:30

## POSTER Session 2

VENUE

<b>P2-01-86 - 95</b>	<b>PS2: Cancer clinical 2</b> <i>Chair: Daria Handkiewicz-Junak (Poland)</i>	<b>Bartok I</b>
<b>P2-02-96 - 105</b>	<b>PS2: Cancer Diagnosis</b> <i>Chair: Marco Centanni (Italy)</i>	<b>Liszt I</b>
<b>P2-03-106 - 115</b>	<b>PS2: Cancer risk stratification</b> <i>Chair: Fabio Maino (Italy)</i>	<b>Liszt II</b>
<b>P2-04-116 - 125</b>	<b>PS2: Cancer Translational</b> <i>Chair: Christine Spitzweg (Germany)</i>	<b>Liszt III</b>
<b>P2-05-126 - 136</b>	<b>PS2: Diagnosis 1</b> <i>Chair: Bernard Corvilain (Belgium)</i>	<b>Mozart I</b>
<b>P2-06-137 - 147</b>	<b>PS2: Hyperthyroidism</b> <i>Chair: Colin Dayan (United Kingdom)</i>	<b>Mozart II</b>
<b>P2-07-148 - 159</b>	<b>PS2: Nodules 2</b> <i>Chair: Ilya Sleptsov (Russian Federation)</i>	<b>Mozart III</b>
<b>P2-08-160 - 168</b>	<b>PS2: Thyroid Hormone and Inflammation</b> <i>Chair: Guia Vannucchi (Italy)</i>	<b>Strauss</b>

12:30 - 13:30

## ETA Industry-sponsored Satellite SYMPOSIUM 2

VENUE  
Patria

## Levothyroxine replacement in the 21st century

Chairs: Laszlo Hegedüs (Copenhagen, Denmark)  
and Petros Perros (Newcastle, United Kingdom)

**Welcome and Introduction**

*Petros Perros, (Pecs, Hungary)*

**The patient voice**

*Janis Hickey (Harrogate, United Kingdom)*

**Epidemiology of unmet patient needs**

*Robin P. Peeters (Rotterdam, Netherlands)*

**Pharmacokinetic and pharmacodynamic considerations**

*Endre V. Nagy (Debrecen, Hungary)*

**Questions**

*All speakers & Chairs*

**Closing remarks**

*Laszlo Hegedüs*

IBSA organized and funded educational symposium



13:30 - 14:15

## Meet the EXPERT 1

VENUE  
Patria

**Thyroid hormone analogues:  
An update**  
*Riccardo Zucchi (Italy)*

13:30 - 14:15

## Meet the EXPERT 2

VENUE  
Bartok II

**Trace Elements and Thyroid function**  
*Michael Zimmermann (Switzerland)*

13:30 - 14:15

## Meet the EXPERT 3

VENUE  
Lehar I-III

**Thyroid cancer after nuclear  
accidents: to screen or not  
to screen for?**  
*Furio Pacini (Italy)*

13:30 - 14:15

## Meet the EXPERT 4

VENUE  
Brahms

**Adverse effects of immune  
checkpoint inhibitors**  
*Maria Alevizaki (Greece)*

14:15 - 15:45

## ORAL Session 4 Thyroid Cancer management

VENUE  
Patria

Chairs: Barbara Jarzab (Poland) and Emese Mezosi (Hungary)

14:15 - 14:30

### OP-04-19

**Second fine-needle aspiration cytology in a series of benign thyroid nodules: are the 2015 ATA guidelines recommendations helpful?**  
*Annalisa Bufano (Italy)*

14:30 - 14:45

### OP-04-20

**Molecular testing by the custom PTC Mass Array Genotyping platform in thyroid fine needle aspirates**  
*Carla Colombo (Italy)*

14:45 - 15:00

### OP-04-21

**Recommendations for radioiodine remnant ablation in differentiated thyroid cancer patients according to 2018 Italian Consensus: does it change anything?**  
*Raffaella Forleo (Italy)*

15:00 - 15:15

### OP-04-22

**Impact on Quality of Life and Tolerability of US-guided Laser Ablation for Iodine Refractory Lymph-node Metastasis of Thyroid Carcinoma**  
*Enrico Papini (Italy)*

15:15 - 15:30

**OP-04-23**

**Predisposing factors of response or resistance to Tyrosine Kinase Inhibitors (TKIs) therapy in metastatic Medullary Thyroid Carcinoma (meta-MTC) patients**

*George Simeakis (Greece)*

15:30 - 15:45

**OP-04-24**

**Occurrence of second primary malignancy in Medullary Thyroid Carcinoma (MTC) patients**

*George Simeakis (Greece)*

14:15 - 15:45

**ORAL Session 5** **Thyroid signal during development**

VENUE  
**Bartok II**

Chairs: Veerle Darras (Belgium) and László Hunyady (Hungary)

14:15 - 14:30

**OP-05-25**

**In Vivo Chemical Genetic Screens in Zebrafish Embryos Reveal Signaling Pathways Regulating Early Thyroid Development**

*Robert Opitz (Germany)*

14:30 - 14:45

**OP-05-26**

**Treatment with T3 versus natural process: Comparative analysis of transcriptomes**

*Laurent Sachs (France)*

14:45 - 15:00

**OP-05-27**

**Asynchronous differentiation of thyroid progenitors in vivo**

*Ellen Johansson (Sweden)*

15:00 - 15:15

**OP-05-28**

**Glis3 as a critical regulator of thyroid primordium specification**

*Giuditta Rurale (Italy)*

15:15 - 15:30

**OP-05-29**

**Chronic exposure to microcystin-Lr reduces thyroid hormone levels by activating p38/mapk and mek/erk signal pathway**

*Jihai Chen (China)*

15:30 - 15:45

**OP-05-30**

**Iodine deficiency leads to differential thyroid-specific gene expression and tissue microstructure in dehal1 knockout mice**

*Jorge García Giménez (Spain)*

16:00 - 17:00

ETA Industry-sponsored Satellite **SYMPOSIUM 3**

VENUE  
Patria

**RAI-R DTC: Are we managing patients or tumours ?  
A consideration of the holistic management of patients with  
progressive, advanced RAI-R DTC**

16:00 - 16:10	<b>Introduction</b> Goal of the symposium, introductions to the panel and introduction to the patient case study <i>Chair: Dr. Marcia Brose (Philadelphia, USA)</i>
16:10 - 16:20	<b>Monitoring of the RAI-Refractory DTC</b> – what does active surveillance actually look like <i>Interactive Panel discussion</i>
16:20 - 16:30	<b>Prehabilitation – what is that and how is it relevant to RAI-R DTC?</b> <i>Interactive Panel discussion</i>
16:30 - 16:40	<b>Supporting the patients on TKI therapy</b> – The critical immediate post initiation phase <i>Interactive Panel discussion</i>
16:40 - 16:50	<b>Ongoing support for the patients on TKI therapy</b> – The maintenance phase. Is the support any different ? <i>Interactive Panel discussion</i>
16:50 - 17:00	<b>Questions from the audience</b> <i>Chair: Dr. Marcia Brose (Philadelphia, USA)</i>
17:00	<b>Close</b>

EISAI organized and funded educational symposium

17:00 - 18:30

**SYMPOSIUM 3** **New Insights in Graves' orbitopathy**

VENUE  
Patria

*Chairs: Tomasz Bednarczuk (Poland) and Claudio Marcocci (Italy)*

17:00 - 17:25	<b>Current understanding in the aetiopathogenesis of Graves' orbitopathy</b> <i>Terry Smith (United States)</i>
17:30 - 17:55	<b>Imaging techniques in the diagnosis and consequences for Graves' orbitopathy management</b> <i>Endre Nagy (Hungary)</i>
18:00 - 18:25	<b>New medical treatment modalities in moderate to severe Graves' orbitopathy</b> <i>Luigi Bartalena (Italy)</i>

17:00 - 18:30

**SYMPOSIUM 4** **Thyroid Cancer translational Symposium**VENUE  
**Bartok II**

Chairs: Clara Alvarez (Spain) and Orsolya Dohán (Hungary)

17:00 - 7:17

**TERT aberrations in Thyroid Cancer***Catharina Larsson (Sweden)*

17:22 - 17:39

**DNA methylation as marker of prognosis in differentiated thyroid cancer***Mireia Jorda (Spain)*

17:44 - 18:01

**Novel molecular markers of Differentiated Thyroid Cancer progression***Christopher McCabe (United Kingdom)*

18:06 - 18:23

**miRNA as prognostic factors in the follow-up of Medullary Thyroid Cancer***Maria Grazia Borrello (Italy)*

18:35 - 18:50

**LISSITZKY Award**VENUE  
**Patria**

Chairs: Leonidas Duntas (Greece) and Laszlo Hegedüs (Denmark)

ETA

European  
THYROID  
Association



Visit us at the Karger Publishers  
booth no. 2



Official journal of



For more details and planned activities  
during the ETA 2019, follow us on  
Facebook @**EuropeanThyroidJournal**

**KARGER**

K119221

08:00 - 09:30

**SYMPOSIUM 5** **Joint Symposium ETA/EANM:  
Impact of the new classification**VENUE  
Patria

Chairs: Laura Fugazzola (Italy) and Tamas Solymosi (Hungary)

- 
- 08:00 - 08:25 **Impact on pathological classification (or for the Pathologist)**  
*Guido Fadda (Italy)*
- 
- 08:30 - 08:55 **Impact on clinical classification (or for the Clinician)**  
*Romana Teodora Netea-Maier (Netherlands)*
- 
- 09:00 - 09:25 **Impact on indication for treatment (or for Nuclear Medicine)**  
*Markus Luster (Germany)*
- 

08:00 - 09:30

**SYMPOSIUM 6** **Novel aspects of Thyroid hormone signaling**VENUE  
Bartok II

Chairs: István Ábrahám (Hungary) and Samuel Refetoff (United States)

- 
- 08:00 - 08:25 **TR ligand binding**  
*John Schwabe (United Kingdom)*
- 
- 08:30 - 08:55 **Physiological relevance of canonical and non-canonical thyroid hormone signaling**  
*Lars Christian Moeller (Germany)*
- 
- 09:00 - 09:25 **Clinical disorders of thyroid hormone signaling (TR alpha and beta)**  
*Carla Moran (United Kingdom)*
- 

10:00 - 11:30

**ORAL Session 6** **Improving clinical management  
of Thyroid Cancer**VENUE  
Patria

Chairs: Ferenc Gyóry (Hungary) and Thera Links (Netherlands)

- 
- 10:00 - 10:15 **OP-06-31**  
**Avoiding overdiagnosis through clinical guideline recommendations: the impact on real-life practice according to the Italian Thyroid Cancer Observatory (ITCO)**  
*Giorgio Grani (Italy)*
- 
- 10:15 - 10:30 **OP-06-32**  
**Thyroid cancer incidence and characteristics in a cohort of patients treated with chemo and radiotherapy for childhood cancer: a single centre experience**  
*Martina Tavarelli (Italy)*
- 
- 10:30 - 10:45 **OP-06-33**  
**Non thyroidal second primary malignancies in differentiated thyroid cancer (DTC) patients: is the incidence increased comparing to the general population and could it be a radioiodine's fault?**  
*Virginia Cappagli (Italy)*
-

10:45 - 11:00	<b>OP-06-34</b> <b>Association of CHEK2 variants with papillary thyroid cancer risk but not with disease outcome</b> <i>Magdalena Wycislik (Poland)</i>
11:00 - 11:15	<b>OP-06-35</b> <b>Controversial Management of Differentiated Thyroid Carcinoma between 1-4 cm. Challenging Current ATA Guidelines Recommendations</b> <i>Juan Carlos Galofré (Spain)</i>
11:15 - 11:30	<b>OP-06-36</b> <b>Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center</b> <i>Carlotta Giani (Italy)</i>

10:00 - 11:30

## **ORAL Session 7** Thyroid Hormone action in tissue function and inflammation

Chairs: Barbara Demeneix (France) and Monika Katko (Hungary)

VENUE  
**Bartok II**

10:00 - 10:15	<b>OP-07-37</b> <b>Loss of stearoyl-CoA desaturase 1 affects thyroid hormone action and induces epigenetic modifications in cardiomyocytes</b> <i>Adam Olichwier (Poland)</i>
10:15 - 10:30	<b>OP-07-38</b> <b>Role of thyroid hormone in the control of neural stem cell fate throughout life</b> <i>Lucile Butruille (France)</i>
10:30 - 10:45	<b>OP-07-39</b> <b>Naringenin increases pituitary Sirt1/TSH ratio and induces ultrastructural changes in the thyroids of old-aged male Wistar rats</b> <i>Marko Miler (Serbia)</i>
10:45 - 11:00	<b>OP-07-40</b> <b>Evaluation of the effects of Triiodothyronine treatment in ZSF1 rats, an animal model of Metabolic Syndrome</b> <i>Marta Borges-Canha (Portugal)</i>
11:00 - 11:15	<b>OP-07-41</b> <b>Comparison of the effects of short and long TSHR-derived cyclic peptides to induce tolerance in Graves' disease and orbitopathy</b> <i>Martin Ungerer (Germany)</i>
11:15 - 11:30	<b>OP-07-42</b> <b>Hyaluronan oligosaccharides promote inflammation and downregulate the expression of thyroid-specific genes via Toll-like receptors 2 and 4 (TLR-2 and TLR-4) and CD44</b> <i>Rosaria Ruggeri (Italy)</i>

11:30 - 12:30

## POSTER Session 3

VENUE

<b>P3-01-167 - 177</b>	<b>PS3: Autoimmunity 2</b> <i>Chair: Thomas Brix (Denmark)</i>	<b>Bartok I</b>
<b>P3-02-178 - 187</b>	<b>PS3: Cancer Case Reports</b> <i>Chair: Peter Reismann (Hungary)</i>	<b>Liszt I</b>
<b>P3-03-188 - 199</b>	<b>PS3: Cancer clinical 3</b> <i>Chair: Joao Jacome De Castro (Portugal)</i>	<b>Liszt II</b>
<b>P3-04-200 - 209</b>	<b>PS3: Cancer Treatment</b> <i>Chair: Istvan Takacs (Hungary)</i>	<b>Liszt III</b>
<b>P3-05-210 - 221</b>	<b>PS3: Diagnosis 2</b> <i>Chair: Brigitte Decallonne (Belgium)</i>	<b>Mozart I</b>
<b>P3-06-222 - 233</b>	<b>PS3: Surgery</b> <i>Chair: Alessandro Antonelli (Italy)</i>	<b>Mozart II</b>
<b>P3-07-234 - 241</b>	<b>PS3: Thyroid Gland</b> <i>Chair: Miklós Bodor (Hungary)</i>	<b>Mozart III</b>
<b>P3-08-242 - 248</b>	<b>PS3: Thyroid Hormone, metabolism and inflammation</b> <i>Chair: Csaba Balázs (Hungary)</i>	<b>Strauss</b>

12:30 - 13:30

## ETA Industry-sponsored Satellite SYMPOSIUM 4

VENUE  
Patria

## Thyroid Cancer in focus: what comes next?

Chair: Johannes Smit (Nijmegen, Netherlands)

12:30 - 12:40	<b>Focus on 2019: the current status</b> <i>Johannes Smit (Netherlands)</i>
12:40 - 13:00	<b>Focus on the patient: optimizing TKI treatment in RAI-R DTC</b> <i>Jaume Capdevila (Spain)</i>
13:00 - 13:15	<b>Focus on precision: options in thyroid cancer</b> <i>Robin Peeters (Netherlands)</i>
13:15 - 13:30	<b>Panel Q&amp;A</b> Moderated by the chair

BAYER organized and funded educational symposium



13:30 - 14:15

## Meet the EXPERT 5

VENUE  
Patria

### Guidelines on Graves' disease

*Simon Pearce (United Kingdom)*

13:30 - 14:15

## Meet the EXPERT 6

VENUE  
Bartok II

### Conception, birth and development of a clinical trial on advanced thyroid cancer

*Manisha H. Shah (United States)*

13:30 - 14:15

## Meet the EXPERT 7

VENUE  
Lehar I-III

### Common genetic variants: why of interest?

*Marco Medici (Netherlands)*

13:30 - 14:15

## Meet the EXPERT 8

VENUE  
Brahms

### Endocrine Disruptors

*Barbara Demeneix (France)*

14:30 - 16:00

## ORAL Session 8 Thyroid Cancer: from bench to bed side

VENUE  
Patria

Chairs: Romana Teodora Netea-Maier (Netherlands) und Zsuzsanna Valkusz (Hungary)

14:30 - 14:45

### OP-08-43

#### Molecular profile and radioiodine resistance in papillary thyroid carcinoma

*Carla Colombo (Italy)*

14:45 - 15:00

### OP-08-44

#### Whole Exome Sequencing (WES) identifies potentially actionable molecular variants in the primary tumor and metastasis of radioiodine (RAI) resistant advanced thyroid cancer

*Ralf Paschke (Canada)*

15:00 - 15:15

### OP-08-45

#### Fusion Genes in Papillary Thyroid Cancer in Pediatric Patients

*Barbora Pekova (Czech Republic)*

15:15 - 15:30

### OP-08-46

#### Signatures of mutational processes in noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTPs).

*Malgorzata Oczko-Wojciechowska (Poland)*

15:30 - 15:45

### OP-08-47

#### Presurgical Circulating Tumoral DNA Analysis by NGS in Patients Affected by Medullary Thyroid Carcinoma: Feasibility and Prognostic Role

*Raffaele Ciampi (Italy)*

15:45 - 16:00

### OP-08-48

#### Treatment of Primary Anaplastic Thyroid Cancer Cells, (obtained from Biopsy, or Fine Needle Aspiration) with two Tyrosine Kinase Inhibitors: CLM29 and CLM3.

*Giusy Elia (Italy)*

14:30 - 16:00

**ORAL Session 9 Hyperthyroidism**

Chairs: Luigi Bartalena (Italy) and Ágota Muzsnai (Hungary)

VENUE  
**Bartok II**

14:30 - 14:45

**OP-09-49****Mental health is negatively impacted by hyperthyroidism and differs between Graves' disease and toxic nodular goiter. A nationwide register-based study.***Thomas Brix (Denmark)*

14:45 - 15:00

**OP-09-50****The consequences of hyperthyroidism for bone microstructure before and after treatment - a longitudinal clinical study using HR-pQCT***Pia Nicolaisen (Denmark)*

15:00 - 15:15

**OP-09-51****Early intensive control of hyperthyroidism in Graves' disease is associated with improved survival regardless of treatment modality***Onyebuchi Okosieme (United Kingdom)*

15:15 - 15:30

**OP-09-52****Characterization of fusion proteins with either one or two thyroid stimulating hormone receptor (TSHR) A domains in Graves' disease patient serum samples***Martin Ungerer (Germany)*

15:30 - 15:45

**OP-09-53****Analysis of Clinical Activity Score (CAS) at baseline in a large cohort of patients with moderate to severe Graves' Orbitopathy (GO)***Giulia Lanzolla (Italy)*

15:45 - 16:00

**OP-09-54****Efficacy of Rituximab in patients with active moderate-severe Graves' Orbitopathy: outcomes of different dose regimens***Elisa Lazzaroni (Italy)*

16:10 - 17:10

**Short Call Abstracts**

Chair: Leonidas Duntas (Greece)

VENUE  
**Patria**

17:10 - 17:50

**Pinchera Prize Lecture**

Chairs: Leonidas Duntas (Greece) and Laszlo Hegedüs (Denmark)

VENUE  
**Patria**

18:00 - 19:00

**GENERAL ASSEMBLY**VENUE  
**Patria**

19:30 - 22:30

**ETA NETWORK DINNER**

# Notes

MONDAY

Scientific Programme

08:00 - 08:30

**RESEARCH GRANT 2017 - Winner Presentations**VENUE  
Patria

Chairs: Leonidas Duntas (Greece)

- 
- |               |  |
|---------------|--|
| 08:00 - 08:10 | <b>Genetic markers of thyroid function: a step towards personalized medicine?</b><br><i>Marco Medici (Netherlands)</i> |
|---------------|--|
- 
- |               |   |
|---------------|---|
| 08:10 - 08:20 | <b>Treatment of differentiated iPS cells with MCT8-rescuing phenylbutyrate</b><br><i>Doreen Braun (Germany)</i> |
|---------------|---|
- 
- |               |  |
|---------------|--|
| 08:20 - 08:30 | <b>Effects of novel thyroid hormone metabolites on hepatic metabolism of trace elements</b><br><i>Lutz Schomburg (Germany)</i> |
|---------------|--|
- 

08:30 - 10:30

**ORAL Session 10 Young Investigators / Clinical + Translational**VENUE  
Patria

Chairs: Simone De Leo (Italy) and Rodrigo Moreno-Reyes (Belgium)

- 
- |               |  |
|---------------|--|
| 08:30 - 08:50 | <b>OP-10-55</b><br><b>Duration of over- and undertreatment of hypothyroidism is associated with increased cardiovascular risk.</b><br><i>Mads Lillevang-Johansen (Denmark)</i> |
|---------------|--|
- 
- |               |   |
|---------------|---|
| 08:50 - 09:10 | <b>OP-10-56</b><br><b>Micropapillary thyroid cancer (mPTC): results of the first European, prospective, single-center observational trial</b><br><i>Maria Cristina Campopiano (Italy)</i> |
|---------------|---|
- 
- |               |  |
|---------------|--|
| 09:10 - 09:30 | <b>OP-10-57</b><br><b>Thyroid function and traditional risk factors for cardiovascular disease: A Mendelian Randomization study.</b><br><i>Aleksander Kuś (Poland)</i> |
|---------------|--|
- 
- |               |   |
|---------------|---|
| 09:30 - 09:50 | <b>OP-10-58</b><br><b>Association of maternal thyroid function with birth weight: an individual-participant data meta-analysis</b><br><i>Arash Derakhshan (Netherlands)</i> |
|---------------|---|
- 
- |               |  |
|---------------|--|
| 09:50 - 10:10 | <b>OP-10-59</b><br><b>Comparative clinical, genetic and transcriptomic characterization of RAI-sensitive and RAI-refractory thyroid cancer identifies IGF2 as potential driver of RAI resistance</b><br><i>Thomas Crezee (Netherlands)</i> |
|---------------|--|
- 
- |               |  |
|---------------|--|
| 10:10 - 10:30 | <b>OP-10-60</b><br><b>Iodine fortification dramatically changes the spectrum in both thyrotoxicosis and hypothyroidism subtypes.</b><br><i>Mads Petersen (Denmark)</i> |
|---------------|--|
-



08:30 - 10:30

**ORAL Session 11** Young Investigators / Basic

VENUE  
**Bartok II**

Chairs: Anita Boelen (Netherlands) and Graham R. Williams (United Kingdom)

- 
- 08:30 - 08:50    **OP-11-61**  
**Functional characterization of SLC17A4, a novel player in the thyroid hormone transport field**  
*Stefan Groeneweg (Netherlands)*
- 
- 08:50 - 09:10    **OP-11-62**  
**Altered thyroid function regulates adrenal cortex development and function in mice**  
*Konrad Patyra (Finland)*
- 
- 09:10 - 09:30    **OP-11-63**  
**The intracellular metabolism of thyroid hormone regulates the tumor progression of skin cancer**  
*Annunziata Gaetana Cicatiello (Italy)*
- 
- 09:30 - 09:50    **OP-11-64**  
**The thyroid hormone transporter Mct8 is indispensable for adult hippocampal neurogenesis**  
*Steffen Mayerl (United Kingdom)*
- 
- 09:50 - 10:10    **OP-11-65**  
**Differential expression pro-inflammatory cytokines during brafv600e-induced thyroid tumor development**  
*Carmen Moccia (Sweden)*
- 
- 10:10 - 10:30    **OP-11-66**  
**six1 is overexpressed in anaplastic thyroid cancer and promotes epithelial-to-mesenchymal transition**  
*Adrián Acuña-Ruiz (Spain)*
- 

11:00 - 13:00

**ORAL Session 12** Pregnancy, Hypothyroidism and Aging

VENUE  
**Patria**

Chairs: Tim Korevaar (Netherlands) and Ferenc Péter (Hungary)

- 
- 11:00 - 11:15    **OP-12-67**  
**Frequency of maternal thyroid function abnormalities and thyroid autoimmunity among 14,323 pregnant women in the North Denmark Region**  
*Louise Knøsgaard (Denmark)*
- 
- 11:15 - 11:30    **OP-12-68**  
**Thyroid function and circulating metabolites: evidence from observational and Mendelian randomization studies**  
*Nicolien van Vliet (Netherlands)*
- 
- 11:30 - 11:45    **OP-12-69**  
**Levels of thyroid stimulating hormone and the risk of cardiovascular morbidity: meta-analysis of 5 cohort studies**  
*Line Tang Moellehave (Denmark)*
- 

TUESDAY

Scientific Programme

- |               |   |
|---------------|---|
| 11:45 - 12:00 | <b>OP-12-70</b><br><b>Increased risk of dementia in autoimmune hypothyroidism.</b><br><b>A Danish nationwide register-based study</b><br><i>Marianne Thvilum (Denmark)</i>  |
| 12:00 - 12:15 | <b>OP-12-71</b><br><b>Targeted identification of resistance to exogenous T4 in humans</b><br><i>Cristian González-Guerrero (Spain)</i>  |
| 12:15 - 12:30 | <b>OP-12-72</b><br><b>Restoration of euthyroidism in hypothyroid women changes bone microarchitecture but not bone strength, as investigated by High-Resolution peripheral Quantitative Computed Tomography (HR-pQCT)</b><br><i>Maria Lohman Pedersen (Denmark)</i> |
| 12:30 - 12:45 | <b>OP-12-73</b><br><b>Thyroid autoimmunity and intracytoplasmic sperm injection outcome: a systematic review and meta-analysis.</b><br><i>Kris Poppe (Belgium)</i>  |
| 12:45 - 13:00 | <b>OP-12-74</b><br><b>Drinking water iodine content is associated with longevity in older adults: 20 year follow-up of the Randers-Skagen study.</b><br><i>Johannes Riis Jensen (Denmark)</i>   |

11:00 - 13:00

**ORAL Session 13 Thyroid Cancer: from bed side to bench**VENUE  
**Bartok II**

Chairs: Rossella Elisei (Italy) and Miklós Tóth (Hungary)

- |               |  |
|---------------|--|
| 11:00 - 11:15 | <b>OP-13-75</b><br><b>miRNA diagnostic signature of human thyroid cancer outperforms classical mutational status detection</b><br><i>Manuel Saiselet (Belgium)</i>                     |
| 11:15 - 11:30 | <b>OP-13-76</b><br><b>Clonality studies in papillary thyroid cancer: evidences of intra-tumor heterogeneity</b><br><i>Marina Muzza (Italy)</i>   |
| 11:30 - 11:45 | <b>OP-13-77</b><br><b>Secretion of cancer-associated microRNAs via exosomes after TSH stimulation of thyroid cancer cells</b><br><i>Jelena Jankovic (Serbia)</i>                       |
| 11:45 - 12:00 | <b>OP-13-78</b><br><b>Functional and genetic studies in PTC to assess TKI efficacy</b><br><i>Miguel Angel Chenlo Miranda (Spain)</i>   |
| 12:00 - 12:15 | <b>OP-13-79</b><br><b>Gender differences in tumor development and targeted therapy in a BrafV600E-induced mouse model of papillary thyroid cancer</b><br><i>Elin Schoultz (Sweden)</i> |

12:15 - 12:30	<b>OP-13-80</b> <b>Analysis of copy number variation in Medullary Thyroid cancer and correlation with mutational profile and RET expression</b> <i>Teresa Ramone (Italy)</i>
12:30 - 12:45	<b>OP-13-81</b> <b>The clonality of Medullary Thyroid Cancer could be related to the type of somatic mutation and its allelic frequency</b> <i>Cristina Romei (Italy)</i>
12:45 - 13:00	<b>OP-13-82</b> <b>Mesenchymal stem cell - mediated sodium iodide symporter (NIS) reporter gene delivery in glioblastoma</b> <i>Carolin Kitzberger (Germany)</i>

13:10 - 14:40

### **SYMPOSIUM 7** Subclinical Hypothyroidism: What has been missed

VENUE  
Patria

Chairs: Laszlo Bajnok (Hungary) and Ulla Feldt-Rasmussen (Denmark)

13:10 - 13:35	<b>Tissue signal of subclinical hypothyroidism other than serum TSH</b> <i>Leonidas Duntas (Greece)</i>
13:40 - 14:05	<b>Adherence to therapy and the economic burden of subclinical hypothyroidism</b> <i>Peter Taylor (United Kingdom)</i>
14:10 - 14:35	<b>Avoiding overtreatment and undertreatment by an individually tailored dose or alternative thyroxine preparations</b> <i>Marco Centanni (Italy)</i>

13:10 - 14:40

### **SYMPOSIUM 8** Central Control of Thyroid hormone action

VENUE  
Bartok II

Chairs: Eric Fliers (Netherlands) and Balázs Gereben (Hungary)

13:10 - 13:35	<b>Tanycytes control the hormonal output of the hypothalamic-pituitary-thyroid axis</b> <i>Helge Müller-Fielitz (Germany)</i>
13:40 - 14:05	<b>Role of endocannabinoids and glutamate in the regulation of TRH release in the median eminence by tanycytes</b> <i>Csaba Fekete (Hungary)</i>
14:10 - 14:35	<b>The type 2 deiodinase polymorphism: basic and translational implications</b> <i>Antonio Bianco (United States)</i>

14:40 - 15:00

### **PRIZE CEREMONY and Closure**

VENUE  
Patria

Chairs: Leonidas Duntas (Greece)  
and Laszlo Hegedüs (Denmark)

Notes

ETA

★ European  
★ THYROID  
★ Association

# Save the Date



**8-13  
September  
2020**

Qujiang  
International  
Conference and  
Exhibition Center  
Xi'an, Shaanxi,  
China

*The city of Xi'an is famous for her ancient history, cultural richness and tourist resources and is becoming one of the world's most popular congress destinations. It has been regarded as one of the four greatest cities of ancient civilization in the world. In addition, with the longest history and most influence among its Chinese counterparts, Xi'an has been reputed as the cradle of Chinese people and civilization, as well as the representative of Chinese culture. It was built 3,100 years ago and had been made the capital city for 1,200 years for 13 dynasties including Zhou, Qin, Han, and Tang, etc., winning the honor of land of empire for centuries. Xi'an has been the first Chinese city open up to the outside world and the starting point of the well-known Silk Road.*

Welcome  
to **Xi'an**

[www.ITC2020.org](http://www.ITC2020.org)




## Transparency Declaration

The Executive Committee and the Standing Office of the ETA are most grateful to the following ETA Corporate members and all other sponsors for their generous logistical support of the ETA 2019 Annual Meeting


Bayer HealthCare Pharmaceuticals Inc.	30.000 €	for a satellite symposium
Berlin Chemie AG	3.000 € 1.500 €	for an exhibition space sponsorship of the Young Investigator Prize
Bioscientifica Ltd.	3.000 €	for an exhibition space
Eisai Europe Ltd.	30.000 €	for a satellite symposium
Elesta S.r.l.	3.000 €	for an exhibition space
EXELIXIS	7.500 €	for an exhibition space
GE Hungary Ltd.		Provision of ultrasound machines
IASON GmbH	3.000 €	for an exhibition space
IBSA Institut Biochimique SA	30.000 € 12.500 €	for a satellite symposium for an exhibition space Provision of congress bags
Medtronic International Trading Sarl	7.500 €	for an exhibition space
Merck KGaA	30.000 € 7.500 €	for a satellite symposium for an exhibition space ETA Pinchera Prize: the sponsorship comprises the value of 3.000 € for the prize plus reimbursement of the travel expenses (economy class flights) and congress registration fee
RF Medical Co. Ltd	3.000 €	for an exhibition space
STARmed Co., Ltd.	3.000 €	for an exhibition space Provision of lanyards
Wisepress Ltd.	1.500 €	for an exhibition space

*Correct at time of printing*

## Exhibitor Plan



Aula - Conference Level



Entrance Level

